A Phase 3, Prospective, Double-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection As Compared To Saline Placebo Injection In The Treatment Of Plantar Fasciitis

Trial Profile

A Phase 3, Prospective, Double-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection As Compared To Saline Placebo Injection In The Treatment Of Plantar Fasciitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs DHACM (Primary)
  • Indications Plantar fasciitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors MiMedx
  • Most Recent Events

    • 02 Aug 2018 According to a MiMedx media release, the study is expected to complete in 2019.
    • 26 Mar 2018 According to a MiMedx media release, company plans to file Biologics License Application (BLA) in the second half of 2020.
    • 16 Jan 2018 According to a MiMedx media release, following the conclusion of this trial, MiMedx intends to file a Biologic License Application (BLA) with the U.S. Food and Drug Administration for AmnioFix Injectable to treat moderate to severe plantar fasciitis pain that has failed conservative treatment for at least 30 days in 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top